9号彩票

您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 元云飞

    职务:肝胆科副主任
    职称:教授、主任医师、博士生导师
    专长:肝胆胰肿瘤的外科治疗和肝癌的介入治疗
    主要简介 详细介绍 预约挂号
    一、基本情况
    职务:肝胆科副主任
    专家门诊时间: 周一上午;周四上午
    专业特长:主要从事肝移植、肝胆胰肿瘤的外科治疗和肝癌的介入治疗。在中国率先应用ICGR15评估肝储备功能,熟练掌握各种复杂的肝切除术(如巨大肝癌切除术、肝尾状叶切除术、扩大半肝切除术,中肝叶切除术)、高位胆管癌根治术和胰十二指肠切除术等,对各种高难度肝胆外科手术及高危患者的围手术期处理积累了丰富的经验。

    二、学习及工作经历: 
      1978年—1983年:中山医学院医学系,获学士学位
      1983年—1986年:中国医学科学院血液学研究所工作
      1986年—1989年:中山医科大学外科学硕士研究生,获医学硕士学位
      1989年—1998年:中山大学附属肿瘤医院工作
      1998年—2000年:Baylor医学院进修学习
      2000年—2001年:美国MD Anderson癌症中心进修学习
      2001年至今:中山大学附属肿瘤医院肝胆科工作

      华南肿瘤学国家重点实验室PI,
      《Chinese Journal of Cancer》杂志(原癌症杂志)编委(2003.01-至今),
      《岭南现代临床外科》杂志编委(2007.03-至今),
      《中华普通外科学文献(电子版)》杂志编委(2007.08-至今),
      《中华肝脏外科手术学电子杂志》编委(2012.12-至今)
      中国医师协会外科医师分会肝脏外科医师委员会委员(2015.05-至今)
      中华医学会肿瘤学分会第九届委员会肝癌学组委员(2013.06-至今)
      中国抗癌协会大肠癌专业委员会肝转移学组委员(2008.12-至今)
      广东省抗癌协会肝癌专业委员会委员/常委 ( 2006-至今)
      广东省医学会外科学分会委员会委员/常委 (2013.02-至今)
      广东省抗癌协会大肠癌专业委员会常委 (2012.11-至今)

    E-mail:yuanyf@sysucc.org.cn
            yuanyf@mail.sysu.edu.cn
    Tel & Fax:(+86 20)8734 3118

       1962年10月出生。1983年毕业于中山医学院,获学士学位。1983年9月至1986年8月在天津市中国医学科学院血液学研究所工作。1986年9月回母校读研究生,师从著名外科学家王吉甫教授。1989年8月毕业,获医学硕士学位。1989年9月起在中山 医科大学肿瘤医院腹科工作,1998年6月肝胆科成立后一直在肝胆科工作,其中1998.8-2001.8在美国进修学习。1991年晋升为主治医师,1997年晋升为副教授,2004年破格晋升为临床研究员,随后转聘为肿瘤外科教授、主任医师。

       主要从事肝胆胰肿瘤的外科治疗和肝癌的介入治疗。2003年9月开展肝移植治疗肝癌。肝移植的开展大大提高了肝外科的手术水平,肝切除术已无手术禁区。熟练掌握各种复杂的肝切除术(如巨大肝癌切除术、肝尾状叶切除术、扩大半肝切除术,中肝叶切除术等)、高位胆管癌根治术和胰十二指肠切除术等。临床工作认真负责,外科技术娴熟,手术精细。

       在国内较早开展肝储备功能的研究,1992年开始应用吲哚靛青绿15分钟储留率(ICGR15)单一指标术前评估肝癌病人肝储备功能,明显降低了肝癌切除术后肝功能衰竭发生率[中华肿瘤杂志1995,17:377]。1997年首次提出对于不能切除的肝癌行肝动脉化疗栓塞,若肝储备功能良好,应使用较大剂量lipiodol栓塞,让lipiodol尽量填满肿瘤,达到肿瘤最大限度坏死,而不出现肝功能衰竭[癌症16:358和癌症16(增刊):39]。在国内较早提出ICGR15评估肝癌病人肝储备功能具有简便、实用、较准确等特点。

      近年来,积极开展结直肠癌肝转移的外科治疗和临床研究,本医疗组每周参加结直肠癌的多学科会诊(Multi-Disciplinary Team, MDT)。本院结直肠癌肝转移的综合治疗在全国具有较好的声誉,本院大部分结直肠癌肝转移的外科治疗由本医疗组完成。积极参与国际交流,2012年7月在法国巴黎Paul Brousse医院学习结直肠癌肝转移的多学科治疗。近6年来(2010-2015)本医疗组完成的原发性肝癌和结直肠癌肝转移外科治疗的病例数一直在肝胆科排名第一,并取得了较理想的疗效。

      受国家卫生部推荐,于1998年获得世界卫生组织奖学金。作为访问学者,1998.9-2000.7在美国Baylor医学院进修,2000.8-2001.8在美国M.D. Anderson癌症中心进修。学习肿瘤分子生物学、肿瘤基因治疗与肝胆肿瘤的外科治疗等。国际上首次发现SYK基因的不表达是由其启动子过甲基化引起(Cancer Research 2001, 61:5558)。2001年8月回国后,继续开展肿瘤分子生物学的研究,医院给本课题组配备了独立的肝癌分子生物学实验室和研究助手,获得多项国家自然科学基金。作为(共同)第一或(共同)通讯作者,论文发表在The Journal of Clinical Investigation, Gastroenterology, Hepatology, Gut, Cancer Research, Clinical Cancer Research, Oncogene等国际知名杂志。同时还致力于肝癌的临床研究和转化研究,获得“中山大学(985工程)转化医学研究示范性项目”,“中山大学临床医学研究5010计划项目”和“广东省高等学校科技创新重点项目”等。

      精心培养研究生,已毕业的研究生留在本院工作,或录取到中山大学附属第三医院和附属第六医院,或在广东、北京、湖南、江西等地三甲医院工作。其中洪健博士研究生获得2013年广东省优秀博士学位论文。

    科研基金:
       (1) 国家自然科学基金面上项目,Rfx6在肝癌干细胞干性特征维持中的作用及机制研究,项目负责人:元云飞,项目编号:81372571,经费:90万人民币,2014.01~2017.12。
      (2) 国家自然科学基金面上项目,肝癌Chk1/SYK(L)通路与靶向治疗,项目负责人:元云飞,项目编号:81172344,经费:69万人民币,2012.01~2015.12。
      (3) 国家自然科学基金面上项目,Chk1 参与肝癌Syk(L)和Syk(S)的表达调控及机制研究,项目负责人:元云飞,项目编号:30972916,经费:32万人民币,2010.01~2012.12。
      (4) 国家自然科学基金面上项目,SYK 作为肝癌复发转移标志物的研究,项目负责人:元云飞,项目编号:30872489,经费:30万人民币,2009.01~2011.12。
      (5) 国家自然科学基金专项基金项目(科学部主任基金),SYK 基因与肝细胞癌侵袭性的研究,项目负责人:元云飞,项目编号:30540047,经费:8万人民币,2006.01~2006.12。
      (6) 国家重点基础研究发展计划(973计划),肿瘤异质性演化机制与个体治疗策略的生物学研究,项目首席科学家:吴仲义,分题骨干,经费:62.5万,2014.01~2018.12
      (7) 中山大学临床医学研究5010计划项目,精准肝切除与综合介入治疗方案治疗肝细胞肝癌合并肝硬化门静脉高压症的临床随机对照研究,项目负责人:元云飞,经费:200 万人民币,2012 .07~2022.7
      (8) 中山大学(985工程)转化医学研究示范性项目,早期肝癌复发转移相关DNA甲基化表型的筛选和预测体系的建立,项目负责人:元云飞,经费:100万人民币,2011~2013。
      (9) 广东省高等学校科技创新重点项目(广东省教育厅),肝细胞肝癌合并肝硬化门静脉高压症的治疗策略,项目负责人:元云飞,项目编号:CXZD1133,经费:25万人民币,2012.1~2014.12。
      (10) 华南肿瘤学国家重点实验室自主课题,项目负责人:元云飞。
         a) SYK(S)的表达与肝细胞癌预后关系的研究。经费:8万人民币,2008。
         b) 不同生物学特征肝细胞癌的异常DNA甲基化模式及其在分子分型中应用的研究,经费:30万人民币,2009。
         c) MicroRNA作为诊断标志物用于鉴别肝局灶性结节增生与肝细胞癌的研究,经费:15万人民币,2010。
         d) Rfx6与肝癌的发生发展,经费:16.8 万人民币,2011。
         e) miR-130b在肝癌发病中的作用及其机制研究,经费:16.8 万人民币,2012。
         f) 缺氧微环境下miR-130b-3p 调控肝癌细胞EMT 和转移的分子机制,经费:25 万人民币,2013
         g) Rfx6 在肝癌干细胞干性特征维持中的作用及机制研究, 经费:24.5万元,2014.
         h) SCAND3在肝癌发病中的作用及其机制研究, 经费:14万元,2015.
      (11) 985-II 工程项目课题,肝细胞癌肿瘤相关基因甲基化的研究,项目负责人:元云飞,经费:30万人民币,2006.1-2007.12
      (12) 美国中华医学基金会(China Medical Board of New York, Inc.),“SYK gene methylation, SYK protein expression, and Hepatocellular carcinoma invasion.” 课题负责人(PI):元云飞, No: 98-677, US$ 70 000,2003.1~2004.12.  
      (13) 广东省科技厅科技计划项目,肿瘤侵袭性相关基因的过甲基化作为肝癌复发转移标志物的研究,项目负责人:元云飞,项目编号:2002B30107,经费:15万民币,2003.1~2005.12。
      (14) 广东省医学科学技术研究基金,肝癌SYK基因的过甲基化的研究,项目负责人:元云飞,项目编号:A2002230 ,经费:1万人民币. 2002~2004。
      (15) 广东省教育厅“千百十工程”优秀人才培养基金项目,肝细胞癌SYK、E-cadherin和TIMP-3 基因过甲基化的研究, 项目负责人:元云飞,项目编号:Q校02009,经费:2万人民币,2002.9~2005.8.
      (16) 中山大学国家重点学科(肿瘤学)建设基金,肝癌SYK、E-cadherin和TIMP-3 基因过甲基化的研究,课题负责人,经费:10万人民币,2003.1~2004.12。
      (17) 中山大学肿瘤中心回国人员启动基金,肝癌hMLH1基因的过甲基化的研究,项目负责人:元云飞,经费:2万人民币, 2003.6~2005.5
      (18) 广东省科委立项课题,预测肝细胞癌术后转移与复发的研究,项目负责人:元云飞,经费:2万人民币,1996~1999。
      (19) 中山医科大学肿瘤中心课题,肝储备功能评估在栓塞化疗治疗肝癌中的应用研究,项目负责人:元云飞,经费:0.3万人民币,1996~1998。
      (20) 中山医科大学肿瘤中心课题,肝脏储备功能的综合评估, 课题负责人:元云飞,经费:0.2万人民币,1993~1995年。
      (21) 中山医科大学肿瘤中心课题,原发性肝癌术前肝储备功能评估的初步研究,课题负责人:元云飞, 经费:0.35万人民币,1991~1993。

    部分论文:
      
    Peer-Reviewed Original Research Articles (* as correspondence author):

    2001-2007:
      (1) Yunfei Yuan, Richard Mendez, Aysegul Sahin, and Jia Le Dai*. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Research 2001, 61(14):5558-5561. (2001 IF=8.302)
      (2) Yunfei Yuan, Hongji Liu, Aysegul Sahin and Jia Le Dai*. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. International Journal of Cancer 2005, 113(4):654–659. (2005 IF=4.7)
      (3) Yunfei Yuan*, Jianping Wang, Jinqing Li, Li Wang, Meixiang Li, Zuli Yang, Changqing Zhang, and Jia Le Dai.  Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clinical Cancer Research 2006, 12(22):6687-6695. (2006 IF=6.177)
      (4) Christina Pramudji, Satoru Shimura, Shin Ebara, Guang Yang, Jianxiang Wang, Chengzhen Ren, Yunfei Yuan, Salahaldin A. Tahir, Terry L. Timme, and Timothy C. Thompson*. In Situ Prostate Cancer Gene Therapy Using a Novel Adenoviral Vector Regulated by the Caveolin-1 Promoter. Clinical Cancer Research, 2001, 7(12):4272-4279.2008:
      (5) Li Xu, Liang Huang, Bin-kui Li, Ya-qi Zhang, Jin-qing Li, Yun-fei Yuan*. Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver. Digestive Surgery 2008, 25(5):376. (2008 IF=1.257)
      (6) Hang Su, Jing Zhao, Yujuan Xiong, Teng Xu, Fan Zhou, Yunfei Yuan, Ying Zhang, Shi-Mei Zhuang*. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutation Research 2008, 641:27-35.
      (7) Xing-Dong Xiong, Jian-Hong Fang, Fu-En Qiu, Jing Zhao, Jiasen Cheng, Yunfei Yuan, Sheng-Ping Li, Shi-Mei Zhuang*. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutation Research, 2008, 643:70-74.
      (8) Teng Xu, Ying Zhu, Qing-Kun Wei, Yunfei Yuan, Fan Zhou, Yi-Yuan Ge,JR Yang, H Su, Shi-Mei Zhuang*. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29(11):2126-2131.

    2009:
      (9) Hang Su, Jian-Rong Yang, Teng Xu, Jun Huang, Li Xu, Yunfei Yuan*, Shi-Mei Zhuang*. MicroRNA-101, Downregulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research 2009, 69(3):1135-42. (2009 IF=7.543)
      (10) Jun Huang, Bin-Kui Li, Gui-Hua Chen, Jin-Qing Li, Ya-Qi Zhang, Guo-Hui Li, Yun-fei Yuan*. Long-Term Outcomes and Prognostic Factors of Elderly Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. Journal of Gastrointestinal Surgery 2009, 13(9):1627-1635. (2009 IF=2.402)

    2010:
      (11) Binkui Li, Wenji Liu, Li Wang, Meixiang Li, Jianping Wang, Liang Huang, Pinzhu Huang, and Yunfei Yuan*. CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17(7):1917-1926. (2010 IF=4.182)
      (12) Binkui Li, Yunfei Yuan*, Guihua Chen, Liru He, Yaqi Zhang, Jinqing Li, Guohui Li, and Wan Yee Lau. Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer. 2010, 10:535-43. (2010 IF=3.153)
      (13) Yu-Xiong Feng, Jiang-Sha Zhao, Jing-Jing Li, Tao Wang, Shu-Qun Cheng, Yunfei Yuan, Fudi Wang, Xiao-Fan Wang, Dong Xie*. Liver Cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF- B signaling pathway. Hepatology, 2010, 51(2):535-544.
      (14) Chunxian Zeng, Ruizhi Wang, Daochuan Li, Xue-Jia Lin, Qing-Kun Wei, Yunfei Yuan, Qing Wang, Wen Chen, and Shi-Mei Zhuang*. A Novel GSK-3 beta–C/EBP alpha–miR-122–Insulin-Like Growth Factor 1 Receptor Regulatory Circuitry in Human Hepatocellular Carcinoma. Hepatology 2010, 52:1702-1712.
      (15) Leilei Chen, Tim Hon Man Chan, Yun-Fei Yuan, Liang Hu, Jun Huang, Stephanie Ma, Jian Wang, Sui-Sui Dong, Kwan Ho Tang, Dan Xie, Yan Li, and Xin-Yuan Guan*. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. The Journal of Clinical Investigation. 2010, 120(4):1178-91.
      (16) Hongxing Zhang, Yun Zhai, Zhibin Hu, Chen Wu, Ji Qian, Weihua Jia, Fuchao Ma, Wenfeng Huang, Lixia Yu, Wei Yue, Zhifu Wang, Peiyao Li, Yang Zhang, Renxiang Liang, Zhongliang Wei, Ying Cui, Weimin Xie, Mi Cai, Xinsen Yu, Yunfei Yuan, Xia Xia, Xiumei Zhang, Hao Yang, Wei Qiu, Jingmin Yang, Feng Gong, Minshan Chen, Hongbing Shen, Dongxin Lin, Yi-Xin Zeng, Fuchu He* & Gangqiao Zhou*. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nature Genetics. 2010, 42(9):755-8.
      (17) Ming Shi, Ji-An Chen, Xiao-Jun Lin, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Ya-Qi Zhang, Jin-Qing Li*. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World Journal of Gastroenterology 2010, 16(2): 264-269.
      (18) Guo-Liang Huang, Bin-Kui Li, Mei-Yin Zhang, Hui-Zhong Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi, Xiao-Qian Chen, Long Huang, An-Hua Li, Bi-Jun Huang, Hong-Hua Li, Hui-Yun Wang*. LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World Journal of Gastroenterology 2010, 16(16): 2046-2054.

    2011:
      (19) Liang Huang, Mei-Xiang Li, Li Wang, Bin-Kui Li, Gui-Hua Chen, Li-Ru He, Li Xu, Yun-Fei Yuan*. Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation. Tumor Biology 2011, 32:233-240. (2011 IF=2.143)
      (20) Leilei Chen, Yun-Fei Yuan(co-first), Yan Li, Tim Hon Man Chan, Bo-Jian Zheng, Jun Huang, Xin-Yuan Guan*. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut 2011, 60(4):534-43. (2011 IF=10.111)
      (21) Pinzhu Huang, Jiliang Qiu, Binkui Li, Jian Hong, Canliang Lu, Li Wang, Jianping Wang, Yezhu Hu, Weihua Jia, Yunfei Yuan*. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clinical Biochemistry 2011, 44:582-589. (2011 IF=2.076)
      (22) Jiliang Qiu, Pinzhu Huang, Qian Liu, Jian Hong, Binkui Li, Canliang Lu, Li Wang, Jianping Wang and Yunfei Yuan*. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine 2011, 9:166. (2011 IF=3.474)
      (23) Can-Liang Lu, Ji-Liang Qiu, Pin-Zhu Huang, Ru-Hai Zou, Jian Hong, Bin-Kui Li, Gui-Hua Chen, Yunfei Yuan*. NADPH Oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biology 2011, 32(6):1173-1182. (2011 IF=2.143)
      (24) Jian Li, George Ka-Kit Lau, Leilei Chen, Sui-sui Dong, Hui-Yao Lan, Xiao-Ru Huang, Yan Li, John M. Luk, Yun-Fei Yuan, Xin-yuan Guan*. Interleukin 17A Promotes Hepatocellular Carcinoma Metastasis via NF-kB Induced Matrix Metalloproteinases 2 and 9 Expression. PLoS ONE 2011, 6(7): e21816.
      (25) Xiang-Ming Lao, Dian Wang, Ming Shi, Guipeng Liu, Shengping Li, Rongping Guo, Yunfei Yuan, Minshan Chen, Jinqing Li, Yaqi Zhang* and Xiaojun Lin*. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatology Research 2011, 41(6): 553-563.
      (26) Qian Zhou, Arthur K.-K. Ching, Wilson K.-C. Leung, Carol Y.-Y. Szeto, Shuk-Mei Ho, Paul K.-S. Chan, Yun-Fei Yuan, Paul B.-S. Lai, Winnie Yeo, Nathalie Wong*. Novel therapeutic potential in targeting   microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. International Journal of Oncology 2011, 38(3):721-731.

    2012:
      (27) Jian Hong, Kaishun Hu, Yunfei Yuan*, Yi Sang, Qiangui Bu, Guihua Chen, Longjun Yang, Binkui Li, Pinzhu Huang, Dongtai Chen, Yi Liang, Ruhua Zhang, Jingxuan Pan, Yi-Xin Zeng, and Tiebang Kang*. CHK1 targets spleen tyrosine kinase(L) for proteolysis in hepatocellular carcinoma. The Journal of Clinical Investigation 2012, 122(6):2165-2175. (2012 IF=12.812)
      (28) Qing-an Zeng, Jiliang Qiu, Jian Hong, Yi Li, Shengping Li, Ruhai Zou, Pinzhu Huang, Binkui Li, Yun Zheng, Xiangming Lao and Yunfei Yuan*. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. European Journal of Gastroenterology & Hepatology. 2012, 24(5):575-82. (2012 IF=1.915)
      (29) Qing-An Zeng, Jiliang Qiu, Ruhai Zou, Yijie Li, Shengping Li, Binkui Li, Pinzhu Huang, Jian Hong, Yun Zheng, Xiangming Lao, Yunfei Yuan*. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study. BMC Cancer 2012, 12(1):148. (2012 IF=3.333)
      (30) Ru-hai Zou, An-hua Li, Feng Han, Jiang Hong, Bin-kui Li, Wei Huang, Liang Huang, Yun-fei Yuan*. Liver hypertrophy and accelerated growth of implanted tumors in nonembolized liver of rabbit after left portal vein embolization. Journal of Surgical Research 2012, 178:256-263 (online Apr 2, 2012) (2012 IF=2.018)
      (31) Ji-Liang Qiu, Pin-Zhu Huang, Jing-Hong You, Ru-Hai Zou, Li Wang, Jian Hong, Bin-Kui Li, Kai Zhou, and Yun-fei Yuan*. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chinese Journal of Cancer 2012, 31(5):223-232. (2014, IF=2.155)
      (32) Dongtai Chen, Wei Xing, Jian Hong, Meibing Wang, Yang Huang, Cuizhen Zhu, Yunfei Yuan, and Weian Zeng*. The Beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Annals of Surgical Oncology 2012, 19:3556–3565
      (33) Pengyuan Yang, Qi-Jing Li, Yuxiong Feng, Yun Zhang, Geoffrey J. Markowitz,  Shanglei Ning, Yuezhen Deng, Jiangsha Zhao, Shan Jiang, Yunfei Yuan, Hong-Yang Wang, Shu-Qun Cheng, Dong Xie*, and Xiao-Fan Wang*. TGF-b-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer Cell. 2012, 22(3), 291–303,
      (34) Pinzhu Huang, Jiliang Qiu, Jinghong You, Jian Hong, Binkui Li, Kai Zhou, Guihua Chen, Yunfei Yuan, and Ruhai Zou*. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers. 2012, 17(5):422-9.
      (35) Tim Hon Man Chan, Leilei Chen, Ming Liu, Liang Hu, Bo-jian Zheng, Vincent Kwok-Man Poon, Pinzhu Huang, Yun-Fei Yuan, Jian-dong Huang, Jie Yang, George Sai-wah Tsao, and Xin-Yuan Guan*. Translationally Controlled Tumor Protein Induces Mitotic Defects and Chromosome Missegregation in Hepatocellular Carcinoma Development. Hepatology 2012, 55:491-505
      (36) Ming Liu, Leilei Chen, Tim Hon Man Chan, Jian Wang, Yan Li, Yan Li, Ting-Ting Zeng, Yun-Fei Yuan, and Xin-Yuan Guan*. Serum and Glucocorticoid Kinase 3 at 8q13.1 Promotes Cell Proliferation and Survival in Hepatocellular Carcinoma. Hepatology 2012, 55:1754-1765
      (37) Guo-Liang Huang, Bin-Kui Li, Mei-Yin Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi, Xiao-Qian Chen, Long Huang, Hui-Zhong Zhang, Wanqing Liu, Bi-Jun Huang, Honghua Li, Xiao-Feng Zheng, Xian-Rong Luo, Hui-Yun Wang*. Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma. PLoS ONE 2012, 7(8): e44061.
      (38) Chan Xie, Li-bing Song, Jue-heng Wu, Jun Li, Jing-ping Yun, Jia-ming Lai, Dong-ying Xie, Bingliang Lin, Yun-fei Yuan, Mengfeng Li*, Zhi-liang Gao*. Upregulator of Cell Proliferation Predicts Poor Prognosis in Hepatocellular Carcinoma and Contributes to Hepatocarcinogenesis by Downregulating FOXO3a . PLoS ONE 2012, 7(7): e40607
      (39) Jian Li, George Lau, Leilei Chen, Yun-Fei Yuan, Jun Huang, John M. Luk, Dan Xie, Xin-Yuan Guan*. Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression. PLoS ONE 2012, 7(9): e46264.

    2013:
      (40) Yan Li, Leilei Chen, Tim Hon Man Chan, Ming Liu, Kar–Lok Kong, Ji–Liang Qiu, Yan Li, Yun–Fei Yuan*, and Xin–Yuan Guan*. SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice. Gastroenterology 2013, 144:179-191 (Epub 2012 Sep 25) (2013 IF=13.926)
      (41) J.-L. Qiu, M.-G. Deng, W Li, R.-H. Zou, B.-K. Li, Y Zheng, X.-M. Lao, K Zhou, Y.-F. Yuan*. Hepatic Resection for Synchronous Hepatic Metastasis from Gastric Cancer. European Journal of Surgical Oncology 2013, 39:694-700 (2013 IF=2.843)
      (42) Ruizhi Wang, Na Zhao, Siwen Li, Jian-Hong Fang, Mei-Xian Chen, Jine Yang, Wei-Hua Jia, Yunfei Yuan* and Shi-Mei Zhuang*. MicroRNA-195 Suppresses Angiogenesis and Metastasis of Hepatocellular Carcinoma by Inhibiting the Expression of VEGF, VAV2, and CDC42. Hepatology 2013, 58(2):642-53. (2013 IF=11.19)
      (43) J Gong, J-P Zhang, B Li, C Zeng, K You, M-X Chen, Y Yuan* and S-M Zhuang*. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32(25):3071-9. (2013 IF=8.559)
      (44) Rongrong Wei, Guo-Liang Huang, Mei-Yin Zhang, Bin-Kui Li, Hui-Zhong Zhang, Ming Shi, Xiao-Qian, Chen, Long Huang, Qing-Ming Zhou, Wei-Hua Jia, X.F. Steven Zheng, Yun-Fei Yuan*, and Hui-Yun Wang*. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clinical Cancer Research 2013, 19(17): 1–12. (2013 IF=8.193)
      (45) Chan Xie, Jueheng Wu, Jingping Yun, Jiaming Lai, Yunfei Yuan, Zhiliang Gao, Mengfeng Li, Jun Li, Libing Song*. MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma. PLoS ONE 2013, 8(5): e64235.
      (46) Leilei Chen, Yan Li, Chi Ho Lin, Tim Hon Man Chan1, Raymond Kwok Kei Chow, Yangyang Song, Ming Liu, Yun-Fei Yuan, Li Fu, Kar Lok Kong, Lihua Qi, Yan Li, Na Zhang, Amy Hin Yan Tong, Dora Lai-Wan Kwong, Kwan Man, Chung Mau Lo, Si Lok, Daniel G Tenen* & Xin-Yuan Guan*. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nature Medicine 2013, 19(2):209-16.
      (47) Qiang Gong, Yong Tao, Jian-Rong Yang, Jun Cai, Yunfei Yuan, Jue Ruan, Jin Yang, Hailiang Liu, Wanghua Li, Xuemei Lu, Shi-Mei Zhuang, San Ming Wang and Chung-I Wu. Identification of medium-sized genomic deletions with low coverage, mate-paired restricted tags. BMC Genomics. 2013, 24;14:51.
      (48) Song Ling Poon, See-Tong Pang, John R. McPherson, Willie Yu,  Kie Kyon Huang, Peiyong Guan, Wen-Hui Weng, Ee Yan Siew, Yujing Liu, Hong Lee Heng, Soo Ching Chong, Anna Gan, Su Ting Tay, Weng Khong Lim, Ioana Cutcutache, Dachuan Huang, Lian Dee Ler, Maarja-Liisa Nairismägi, Ming Hui Lee, Ying-Hsu Chang, Kai-Jie Yu, Waraporn Chan-on, Bin-Kui Li, Yun-Fei Yuan, Chao-Nan Qian, Kwai-Fong Ng, Ching-Fang Wu, Cheng-Lung Hsu, Ralph M. Bunte, Michael R. Stratton, P. Andrew Futreal, Wing-Kin Sung, Cheng-Keng Chuang, Choon Kiat Ong, Steven G. Rozen, Patrick Tan, Bin Tean Teh.  Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool.   Science Translational Medicine 2013, 5:197ra101;
      (49) Zuli Yang, Lijun Huo, Hao Chen, Beibei Ni, Jun Xiang, Liang Kang, Lei Wang, Junsheng Peng, Yunfei Yuan, Jianping Wang*. Hypermethylation and prognostic implication of Syk gene in human colorectal cancer. Medical Oncology 2013, 30(2):586.
      (50) Yingjun Liu, Shengping Li, Xiangbin Wan, Yi Li, Binkui Li, Yaqi Zhang, Yunfei Yuan and Yun Zheng*. Efficacy and safety of thermal ablation in patients with liver metastases. European Journal of Gastroenterology & Hepatology. 2013, 25(4):442-6.
      (51) Xiang-Ming Lao, Guangyu Luo, Liang-Tao Ye, Cheng Luo, Ming Shi, Dian Wang, Rongping Guo, Minshan Chen, Shengping Li*, Xiaojun Lin and Yunfei Yuan. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver International. 2013, 33(4):595-604.
      (52) Yongdong Dai, Lulu Liu, Tingting Zeng, Ying-Hui Zhu, Jiangchao Li, Leilei Chen, Yan Li, Yun-Fei Yuan, Stephanie Ma, Xin-Yuan Guan. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 2013, 436(4):711-8.
      (53) Ru-Hai Zou, Qi-Jiong Li, Ji-Liang Qiu, Ya-Di Liao, Yun-Fei Yuan, An-Hua Li. A modified radiofrequency ablation approach for treating distant lymph node metastasis in two patients with late-stage cancer. Chinese journal of cancer. 2013, 32(10):567-70.
      (54) Ruizhi Wang, Na Zhao, Siwen Li, Jian-Hong Fang, Mei-Xian Chen, Jine Yang, Wei-Hua Jia, Yunfei Yuan, Shi-Mei Zhuang. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 2013, 58(2):642-53.

    2014:
      (55) Jian Hong, Yunfei Yuan*, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai, and Raymond T. Chung*. Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research 2014, 74(6):1845-56 (2014 IF=9.329)
      (56) Binkui Li, Pinzhu Huang, Jiliang Qiu, Yadi Liao, Jian Hong, Yunfei Yuan*. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Medical Oncology, 2014, 31(10): 230. (2014 IF=2.634)
      (57) Jun Huang, Qijiong Li, Yun Zheng, Jingxian Shen, Jiliang Qiu, Binkui Li, Ruhai Zou, Jianping Wang and Yunfei Yuan*. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014, 14:818. (2014 IF=3.362)
      (58) Bin-Kui Li, Pin-Zhu Huang, Ji-Liang Qiu, Ya-Di Liao, Jian Hong and Yun-Fei Yuan*. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagnostic Pathology 2014, 9:226.(2014 IF=2.597)
      (59) Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer chemotherapy and pharmacology. 2014, 4(5):1079-87.
      (60) Stella Chai, Man Tong, Kai Yu Ng, Pak Shing Kwan, Yuen Piu Chan, Tsun Ming Fung, Terence K Lee, Nathalie Wong, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan, Stephanie Ma. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014, 5(14):5725-35.
      (61) Longhui Cao, Yi Chang, Wenqian Lin, Jianhua Zhou, Hongying Tan, Yunfei Yuan, Weian Zeng. Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesthesia & Analgesia. 2014, 118(6):1309-16.
      (62) Yin Xie, Rong-Rong Wei, Guo-Liang Huang, Mei-Yin Zhang, Yun-Fei Yuan, Hui-Yun Wang. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Medical Oncology. 2014, 31(3):844.
      (63) Ming Liu, Yan Li, Leilei Chen, Tim Hon Man Chan, Yangyang Song, Li Fu, Ting-Ting Zeng, Yong-Dong Dai, Ying-Hui Zhu, Juan Chen, Yun-Fei Yuan, Xin-Yuan Guan. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology. 2014, 146(4):1084-96.
      (64) Lulu Liu, Yongdong Dai, Jinna Chen, Tingting Zeng, Yan Li, Leilei Chen, Ying-Hui Zhu, Jiangchao Li, Stephanie Ma, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014, 59(2):531-43.
      (65) Tim Hon Man Chan, Chi Ho Lin, Lihua Qi, Jing Fei, Yan Li, Kol Jia Yong, Ming Liu, Yangyang Song, Raymond Kwok Kei Chow, Vanessa Hui En Ng, Yun-Fei Yuan, Daniel G Tenen, Xin-Yuan Guan, Leilei Chen. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014, 63(5):832-43.

    2015:
      (66) Wei He, Qingli Zeng, Yun Zheng, Meixian Chen, Jingxian Shen, Jiliang Qiu, Miao Chen,  Ruhai Zou, Yadi Liao, Qijiong Li, Xianqiu Wu, Binkui Li* and Yun-Fei Yuan*. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015, 15:263. (2014 IF=3.362)
      (67) Xianqiu Wu, Binkui Li, Jiliang Qiu, Jingxian Shen, Yun Zheng, Qijong Li, Yadi Liao, Wei He, Ruhai Zou and Yunfei Yuan*. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma – A prospective, randomized controlled clinical trial. Journal of Clinical Gastroenterology 2015;49:520-528(2014 IF=3.498)
      (68) Jiliang Qiu, Yun Zheng, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.(2014 IF=3.38)
      (69) Lingxi Jiang, Dora Lai-Wan Kwong, Yan Li, Ming Liu, Yun-Fei Yuan, Li Fu, Xin-Yuan Guan*. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis. 2015, 36(10):1111-20.
      (70) Yangyang Song, Guangjin Pan, Leilei Chen, Stephanie Ma, Tingting Zeng, Tim Hon Man Chan, Lei Li, Qizhou Lian, Raymond Chow, Xiujuan Cai, Yan Li, Ming Liu, Yun Li, Yinghui Zhu, Nathalie Wong, Yun-Fei Yuan, Duanqing Pei, Xin-Yuan Guan*. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015, 149(4):1068-81.
      (71) Man Tong, Tsun-Ming Fung, Steve T Luk, Kai-Yu Ng, Terence K Lee, Chi-Ho Lin, Judy W Yam, Kwok Wah Chan, Fai Ng, Bo-Jian Zheng, Yun-Fei Yuan, Dan Xie, Chung-Mau Lo, Kwan Man, Xin-Yuan Guan, Stephanie Ma. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Stem Cell Reports. 2015, 5(1):45-59.
      (72) Xue-Jia Lin, Yutian Chong, Zhi-Wei Guo, Chen Xie, Xiao-Jing Yang, Qi Zhang, Sheng-Ping Li, Yujuan Xiong, Yunfei Yuan, Jun Min, Wei-Hua Jia, Yusheng Jie, Min-Shan Chen, Mei-Xian Chen, Jian-Hong Fang, Chunxian Zeng, Yaojun Zhang, Rong-Ping Guo, Yuankai Wu, Guoli Lin, Limin Zheng, Shi-Mei Zhuang. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. The Lancet Oncology. 2015, 16(7):804-15.
      (73) Zhong-Guo Zhou, Xing-Rong Zheng, Qian Zhou, Ming Shi, Yao-Jun Zhang, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Xiao-Jun Lin, Xiang-Ming Lao, Sheng-Ping Li. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer. 2015, 34(5):205-16.
      (74) Jian-Hong Fang, Hui-Chao Zhou, Chong Zhang, Li-Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong-Ping Guo, Wei-Hua Jia, Jing-Ping Yun, Min-Shan Chen, Yaojun Zhang, Shi-Mei Zhuang. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015, 62(2):452-65.
      (75) Fang Zheng, Yi-Ji Liao, Mu-Yan Cai, Tian-Hao Liu, Shu-Peng Chen, Pei-Hong Wu, Long Wu, Xiu-Wu Bian, Xin-Yuan Guan, Yi-Xin Zeng, Yun-Fei Yuan, Hsiang-Fu Kung, Dan Xie. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genetics. 2015, 11(2):e1004873.
      (76) Jian Wang, Ming Liu, Leilei Chen, Tim Hon Man Chan, Lingxi Jiang, Yun-Fei Yuan, Xin-Yuan Guan. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015, 6(3):1618-30.
      (77) Sheng-Long Ye*, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina SM YIP, Zhengguang Lu. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2015, 7(6):6639

    2016
      (78) Pinghua Yang, Jiliang Qiu, Jun Li, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, and Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery 2016, 263(4):778–786 (2014 IF=8.327)

    中文论文(第一作者):
      (1) 元云飞,王吉甫,陈少斌. 大鼠胰腺移植术后尿液血栓素B2排泄量的变化. 中华器官移植杂志, 1992,13(1):5-7
      (2) 元云飞,李国辉,李锦清, 等, 术前肝储备功能评估对原发性肝癌手术的价值.  中华肿瘤杂志, 1995, 17(5):377-379.          
      (3) 元云飞,李国辉,李锦清,等. 吲哚靛青绿潴留率对评估肝癌手术风险的价值.  癌症,1996,15(4):277-279
      (4) 元云飞,张亚奇,陈敏山,等. 肝癌术中肝硬化分级的临床意义. 癌症,1997,16(1):58-59,62.
      (5) 元云飞,李锦清,张亚奇,等. 肝癌栓塞化疗前肝储备功能评估的临床意义. 癌症,1997,16(增刊):39-40
      (6) 元云飞,李锦清,张亚奇,等.  原发性肝癌的二步切除(附13例报告).癌症,1997,16(5):358-360
      (7) 元云飞, 李锦清, 张亚奇, 陈敏山, 郭荣平, 林小军, 李国辉. 肝切除术中肝储备功能评估的临床意义. 中华外科杂志, 1999, 37(6):327 ( In Brief )
      (8) 元云飞,李锦清, 杨祖立,汪建平. 肿瘤相关基因过甲基化的研究进展. 癌症. 2002, 21(11):1267-1277. (综述)
      (9) 元云飞,李斌奎,李锦清,张亚奇,郭荣平,林小军,李国辉. 巨大肝癌手术切除治疗的远期疗效. 癌症. 2004, 23(7):821-824. 
      (10) 元云飞,崔伯康,张亚奇,李升平,陈敏山,郭荣平,林小军,陈规划,李锦清. 原位肝脏移植治疗局部晚期肝细胞性肝癌的初步研究--附10例报告. 癌症. 2004, 23(9):981-984
      (11) 元云飞,李锦清,李斌奎,张亚奇,李国辉.影响肝细胞肝癌切除术后长期生存的相关因素. 中国实用外科杂志.2004,24(10):608-611
      (12) 元云飞,汪建平,李锦清, 王莉,刘文姬、崔伯康,杨祖立,张昌卿. DNA甲基化导致肝细胞癌SYK基因失表达. 中国肿瘤临床. 2006, 33(6):307-309

    中文论文 (*通讯作者):
      (13) 李斌奎,崔伯康,元云飞*,李锦清,张亚奇,石明,李国辉. 新TNM分期系统对评价手术切除肝癌预后的意义. 癌症,2005,24(7):769-773
      (14) 黄 俊,李斌奎,元云飞*,崔伯康,李锦清,张亚奇,李国辉. 肝脏局灶性结节性增生38例临床分析并文献复习. 癌症,2005,24(10):1241-1245
      (15) 刘文姬,王 莉,汪建平,李锦清,张昌卿,郑 列,元云飞*. CpG岛甲基化表型和OPCML基因表达与肝细胞癌发生的关系. 癌症 2006, 25(6):696-700
      (16) 黄 俊,郑 列,王 莉, 汪建平,李锦清,张昌卿,元云飞*.肝细胞癌hMLH1基因甲基化与肝癌切除术后辅助性TACE疗效的关系. 中山大学学报(医学科学版)2006,27(4S):3-5
      (17) 洪 健, 元云飞*, 李斌奎, 黄亮, 李锦清, 张亚奇, 李国辉. 67例肝细胞肝癌合并重度肝硬化的手术疗效分析.癌症.2007,26(6):620-623
      (18) 黄 俊,元云飞*,李斌奎,李锦清,张亚奇,李国辉。肝切除术治疗老年原发性肝癌的效果分析。中华普通外科学文献(电子版) 2007,1(3):159-162
      (19) 黄 亮,刘继红,元云飞*,李斌奎. 上皮性卵巢癌肝转移的治疗及预后影响因素。中华普通外科学文献(电子版)2008,2(6):479-483
      (20) 卢灿亮,徐 立,李斌奎,李锦清,张亚奇,元云飞*. 原发性肝癌胃转移1例并文献复习. 岭南现代临床外科 2008,8(3):233
      (21) 黄品助,卢灿亮,李斌奎,洪健,黄亮,王莉,张颖, 元云飞*. OCT4在肝细胞癌中的表达及其临床意义. 癌症,2010,29(1):111-116
      (22) 卢灿亮,黄品助,李斌奎,洪健,黄亮,王莉,张颖,元云飞*.NADPH氧化酶DUOX1在肝细胞癌中的表达及临床意义.中华普通外科学文献(电子版)2010.4(1):10-15
      (23) 邱际亮,元云飞*,李斌奎,卢灿亮,徐瑞华,潘志忠,李锦清,张亚奇,万德森.手术切除结直肠癌肝多个转移瘤的效果分析.中华普通外科学文献(电子版), 2010, 4(3):203-207
      (24) 洪健,邹如海,杨龙君,李斌奎,黄品助,元云飞* .肝细胞癌中全长型脾酪氨酸激酶的表达及其预后价值. 中山大学学报(医学科学版)2011, 32(2):216-218.
      (25) 杨龙君,洪 健,廖亚帝,王 莉,李斌奎,元云飞* .全长型脾酪氨酸激酶对肝细胞癌侵袭和转移的抑制作用. 中山大学学报(医学科学版)2012, 33(1):23-27.

        Created on September 28, 2002,
        Updated on April 8, 2016.

访客通道
员工通道
关注肿瘤医院
留言建议 ×
友情链接:万彩会彩票  永利彩票  盛兴彩票  熊猫彩票  金沙彩票  

免责声明: 本站资料及图片来源互联网文章,本网不承担任何由内容信息所引起的争议和法律责任。所有作品版权归原创作者所有,与本站立场无关,如用户分享不慎侵犯了您的权益,请联系我们告知,我们将做删除处理!